T cell responses against tumor associated antigens and prognosis in colorectal cancer patients

被引:20
作者
Nagorsen, D
Scheibenbogen, C
Letsch, A
Germer, CT
Buhr, HJ
Hegewisch-Becker, S
Rivoltini, L
Thiel, E
Keilholz, U
机构
[1] Charite Univ Med Berlin, Dept Surg, Berlin, Germany
[2] Univ Clin Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[3] Ist Nazl Tumori, I-20133 Milan, Italy
关键词
D O I
10.1186/1479-5876-3-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Spontaneous T cell responses against specific tumor-associated antigens ( TAA) are frequently detected in peripheral blood of tumor patients of various histiotypes. However, little is known about whether these circulating, spontaneously occurring, TAA-reactive T cells influence the clinical course of disease. Methods: Fifty-four HLA-A2 positive colorectal cancer patients had been analyzed for the presence of T cell responses against epitopes derived from the TAA Ep-CAM, her-2/neu, and CEA either by ELISPOT assay or by intracellular cytokine staining. Then, Kaplan-Meier survival analysis was performed comparing T-cell-responders and T-cell-non-responders. For comparison, a group of T-cell-non-responders was compiled stringently matched to T-cell-responders based on clinical criteria and also analyzed for survival. Results: Sixteen out of 54 patients had a detectable T cell response against at least one of the three tested TAA. Two out of 21 patients (9.5%) with limited stage of disease (UICC I and II) and 14 out of 33 patients (42.4%) with advanced disease (UICC III and IV) were T cell response positive. Comparing all T-cell-responders (n = 16) and all T-cell-non-responders (n = 38), no survival difference was found. In an attempt to reduce the influence of confounding clinical factors, we then compared 16 responders and 16 non-responders in a matched group survival analysis; and again no survival difference was found (p = 0.7). Conclusion: In summary, we found no evidence that spontaneous peripheral T cell responses against HLA-A2-binding epitopes of CEA, her-2/neu and Ep-CAM are a strong prognostic factor for survival.
引用
收藏
页数:6
相关论文
共 46 条
[1]  
ALBERS A, 2003, J IMMUNOTHER, V26
[2]  
Banchereau J, 2001, CANCER RES, V61, P6451
[3]   Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings [J].
Belli, F ;
Testori, A ;
Rivoltini, L ;
Maio, M ;
Andreola, G ;
Sertoli, MR ;
Gallino, G ;
Piris, A ;
Cattelan, A ;
Lazzari, I ;
Carrabba, M ;
Scita, G ;
Santantonio, C ;
Pilla, L ;
Tragni, G ;
Lombardo, C ;
Arienti, F ;
Marchianò, A ;
Queirolo, P ;
Bertolini, F ;
Cova, A ;
Lamaj, E ;
Ascani, L ;
Camerini, R ;
Corsi, M ;
Cascinelli, N ;
Lewis, JJ ;
Srivastava, P ;
Parmiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4169-4180
[4]   Immunosurveillance against cancer and immunotherapy - Synergy or antagonism? [J].
Boon, T ;
van Baren, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (03) :252-254
[5]   A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 [J].
Coulie, PG ;
Karanikas, V ;
Colau, D ;
Lurquin, C ;
Landry, C ;
Marchand, M ;
Dorval, T ;
Brichard, V ;
Boon, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) :10290-10295
[6]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998
[7]   Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow [J].
Feuerer, M ;
Beckhove, P ;
Bai, LH ;
Solomayer, EF ;
Bastert, G ;
Diel, IJ ;
Pedain, C ;
Oberniedermayr, M ;
Schirrmacher, V ;
Umansky, V .
NATURE MEDICINE, 2001, 7 (04) :452-458
[8]   Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy [J].
Fong, L ;
Hou, YF ;
Rivas, A ;
Benike, C ;
Yuen, A ;
Fisher, GA ;
Davis, MM ;
Engleman, EG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8809-8814
[9]  
Funada Y, 2003, ONCOL REP, V10, P309
[10]  
Harashima N, 2001, EUR J IMMUNOL, V31, P323, DOI 10.1002/1521-4141(200102)31:2<323::AID-IMMU323>3.0.CO